Liraglutide: Additional Phase III data

Additional data from the 26-week, double-blind, U.S. and Canadian Phase III (LEAD-4) trial in 533 patients taking metformin and rosiglitazone showed that 1.2 mg and 1.8 mg liraglutide produced a signi...